KR100527214B1 - 뉴로키닌-1 수용체 길항제로서의 4-페닐-피리딘 유도체 - Google Patents
뉴로키닌-1 수용체 길항제로서의 4-페닐-피리딘 유도체 Download PDFInfo
- Publication number
- KR100527214B1 KR100527214B1 KR10-2003-7001022A KR20037001022A KR100527214B1 KR 100527214 B1 KR100527214 B1 KR 100527214B1 KR 20037001022 A KR20037001022 A KR 20037001022A KR 100527214 B1 KR100527214 B1 KR 100527214B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- methyl
- compound
- bis
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
mg/정제 | |
활성 물질 | 5 |
락토즈 | 45 |
옥수수 전분 | 15 |
미세정질 셀룰로즈 | 34 |
마그네슘 스테아레이트 | 1 |
총 중량 | 100 |
mg/캡슐 | |
활성 물질 | 10 |
락토즈 | 155 |
옥수수 전분 | 30 |
활석 | 5 |
캡슐 충전 중량 | 200 |
mg/좌약 | |
활성 물질 | 15 |
좌약 부형약 | 1285 |
총 중량 | 1300 |
Claims (16)
- 하기 화학식 IA 또는 IB의 화합물 또는 그의 약학적으로 허용가능한 산 부가염:화학식 IA화학식 IB상기 식에서,R1은 이거나, -NH(CH2)2OH, -NR3C(O)CH3 또는 -NR3C(O)-사이클로프로필이고;R2는 메틸 또는 클로로이고;R3은 수소 또는 메틸이고;R은 수소 또는 -(CH2)2OH이고;n은 1 또는 2이다.
- 제 1 항에 있어서,화학식 IA에서 R2가 메틸인 화합물.
- 제 2 항에 있어서,N-(3,5-비스-트라이플루오로메틸-벤질)-N-메틸-4-o-톨릴-6-[1,2,4]트라이아졸-1-일-니코틴아마이드,N-(3,5-비스-트라이플루오로메틸-벤질)-6-(2-하이드록시-에틸아미노)-N-메틸-4-o-톨릴-니코틴아마이드,4-하이드록시-4'-o-톨릴-3,4,5,6-테트라하이드로-2H-[1,2']바이피리디닐-5'-카복실산 (3,5-비스-트라이플루오로메틸-벤질)-메틸-아마이드,4-(2-하이드록시-에톡시)-4'-o-톨릴-3,4,5,6-테트라하이드로-2H-[1,2']바이피리디닐-5'-카복실산 (3,5-비스-트라이플루오로메틸-벤질)-메틸-아마이드 또는(R)-N-(3,5-비스-트라이플루오로메틸-벤질)-6-(3-하이드록시-피롤리딘-1-일)-N-메틸-4-o-톨릴-니코틴아마이드인 화합물.
- 제 1 항에 있어서,화학식 IA에서 R2가 클로로인 화합물.
- 제 4 항에 있어서,4'-(2-클로로-페닐)-4-하이드록시-3,4,5,6-테트라하이드로-2H-[1,2']바이피리디닐-5'-카복실산 (3,5-비스-트라이플루오로메틸-벤질)-메틸-아마이드인 화합물.
- 제 1 항에 있어서,화학식 IB에서 R2가 메틸인 화합물.
- 제 6 항에 있어서,2-(3,5-비스-트라이플루오로메틸-페닐)-N-[6-(2-하이드록시-에틸아미노)-4-o-톨릴-피리딘-3-일]-N-메틸-아이소부티르아마이드,2-(3,5-비스-트라이플루오로메틸-페닐)-N-[6-(2,3-다이하이드로-[1,4]옥사진-4-일)-4-o-톨릴-피리딘-3-일]-N-메틸-아이소부티르아마이드,N-(6-아세틸아미노-4-o-톨릴-피리딘-3-일)-2-(3,5-비스-트라이플루오로메틸-페닐)-N-메틸-아이소부티르아마이드,N-[6-(아세틸-메틸-아미노)-4-o-톨릴-피리딘-3-일]-2-(3,5-비스-트라이플루오로메틸-페닐)-N-메틸-아이소부티르아마이드,사이클로프로판카복실산 (5-{[2-(3,5-비스-트라이플루오로메틸-페닐)-2-메틸-프로피오닐]-메틸-아미노}-4-o-톨릴-피리딘-2-일)-아마이드,사이클로프로판카복실산 (5-{[2-(3,5-비스-트라이플루오로메틸-페닐)-2-메틸-프로피오닐]-메틸-아미노}-4-o-톨릴-피리딘-2-일)-메틸-아마이드 또는2-(3,5-비스-트라이플루오로메틸-페닐)-N-(6-이미다졸-1-일-4-o-톨릴-피리딘-3-일)-N-메틸-아이소부티르아마이드인 화합물.
- 제 1 항에 있어서,화학식 IB에서 R2가 클로로인 화합물.
- 제 8 항에 있어서,2-(3,5-비스-트라이플루오로메틸-페닐)-N-[4-(2-클로로-페닐)-6-(2-하이드록시-에틸아미노)-피리딘-3-일]-N-메틸-아이소부티르아마이드인 화합물.
- 제 1 항 내지 제 9 항 중 어느 한 항에 따른 화합물 및 약학적으로 허용가능한 부형제를 함유하는, 염증성 질병, 구토 반사 장애, 중추신경계(CNS) 장애 및 요실금으로 구성된 군으로부터 선택된 NK-1 수용체 길항제와 관련된 질병 치료용 약제.
- 삭제
- a) 하기 화학식 II의 화합물을 화학식 III의 화합물과 반응시켜 화학식 IB의 화합물을 제조하거나:화학식 II화학식 III화학식 IB(상기 식에서 R1 및 R2는 제 1 항에 주어진 의미를 가짐),b) 하기 화학식 IV의 화합물을 화학식 V의 화합물과 반응시켜 화학식 IA의 화합물을 수득하거나:화학식 IV화학식 V화학식 IA(상기 식에서 R1 및 R2는 제 1 항에 주어진 의미를 가짐),c) 하기 화학식 VI의 화합물을 화학식 VII의 화합물과 반응시켜 화학식 IA의 화합물을 제조하거나:화학식 VI화학식 VII화학식 IA(상기 식에서 Z는 Cl, Br, I, -OS(O)2C6H4CH3 또는 -OS(O)2CH3이고 치환체의 다른 정의는 제 1 항에 주어짐),d) 하기 화학식 VIII 또는 IX의 화합물을 화학식 XIV의 화합물과 반응시켜 화학식 IA 또는 IB의 화합물을 제조하는 단계:화학식 VIII화학식 IX화학식 XIVR1H화학식 IA화학식 IB(상기 식에서 치환체의 정의는 제 1 항에 주어짐), 및바람직한 경우 수득된 화합물을 약학적으로 허용가능한 산 부가염으로 전환시키는 단계를 포함하는, 제 1 항에 정의된 화학식 I의 화합물의 제조 방법.
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00115846.8 | 2000-07-24 | ||
EP00115846 | 2000-07-24 | ||
PCT/EP2001/008432 WO2002008232A1 (en) | 2000-07-24 | 2001-07-20 | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030015898A KR20030015898A (ko) | 2003-02-25 |
KR100527214B1 true KR100527214B1 (ko) | 2005-11-08 |
Family
ID=8169331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-7001022A KR100527214B1 (ko) | 2000-07-24 | 2001-07-20 | 뉴로키닌-1 수용체 길항제로서의 4-페닐-피리딘 유도체 |
Country Status (38)
Country | Link |
---|---|
US (2) | US6576762B2 (ko) |
EP (1) | EP1305319B1 (ko) |
JP (1) | JP4118673B2 (ko) |
KR (1) | KR100527214B1 (ko) |
CN (1) | CN1192032C (ko) |
AR (1) | AR029875A1 (ko) |
AT (1) | ATE322496T1 (ko) |
AU (2) | AU8200501A (ko) |
BR (1) | BR0112695A (ko) |
CA (1) | CA2416874C (ko) |
CY (1) | CY1106113T1 (ko) |
CZ (1) | CZ2003528A3 (ko) |
DE (1) | DE60118569T2 (ko) |
DK (1) | DK1305319T3 (ko) |
EC (1) | ECSP034446A (ko) |
ES (1) | ES2260265T3 (ko) |
GT (1) | GT200100148A (ko) |
HK (1) | HK1058360A1 (ko) |
HR (1) | HRP20030031A2 (ko) |
HU (1) | HU229231B1 (ko) |
IL (2) | IL153837A0 (ko) |
JO (1) | JO2321B1 (ko) |
MA (1) | MA26933A1 (ko) |
MX (1) | MXPA03000367A (ko) |
MY (1) | MY129224A (ko) |
NO (1) | NO20030353L (ko) |
NZ (1) | NZ523452A (ko) |
PA (1) | PA8522801A1 (ko) |
PE (1) | PE20020258A1 (ko) |
PL (1) | PL366173A1 (ko) |
PT (1) | PT1305319E (ko) |
RU (1) | RU2276139C2 (ko) |
SI (1) | SI1305319T1 (ko) |
TW (1) | TWI287003B (ko) |
UY (1) | UY26851A1 (ko) |
WO (1) | WO2002008232A1 (ko) |
YU (1) | YU2803A (ko) |
ZA (1) | ZA200300219B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101119365B1 (ko) | 2006-05-31 | 2012-03-07 | 에프. 호프만-라 로슈 아게 | 아릴-4-에틴일-아이속사졸 유도체 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1103545T3 (da) * | 1999-11-29 | 2004-03-15 | Hoffmann La Roche | 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
KR100755577B1 (ko) | 2002-04-26 | 2007-09-12 | 일라이 릴리 앤드 캄파니 | 타키키닌 수용체 길항제로서의 트리아졸 유도체 |
EP1501808B1 (en) | 2002-04-26 | 2008-07-02 | Eli Lilly And Company | Tachykinin receptor antagonists |
AU2003300018A1 (en) * | 2002-10-11 | 2004-05-04 | Bristol-Myers Squibb Company | Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents |
WO2005000821A1 (en) * | 2003-06-12 | 2005-01-06 | Eli Lilly And Company | Tachykinin receptor antagonists |
DE602004008631T2 (de) | 2003-07-03 | 2008-07-10 | F. Hoffmann-La Roche Ag | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie |
TWI280239B (en) * | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
CN1984891B (zh) | 2004-07-06 | 2012-08-08 | 弗·哈夫曼-拉罗切有限公司 | 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法 |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
US20060069086A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
BRPI0606187A2 (pt) | 2005-02-25 | 2009-06-09 | Hoffmann La Roche | comprimidos com capacidade de dispersão da substáncia do fármaco melhorada |
US8067662B2 (en) | 2009-04-01 | 2011-11-29 | Aalnex, Inc. | Systems and methods for wound protection and exudate management |
US7816577B2 (en) | 2006-02-13 | 2010-10-19 | Aalnex, Inc. | Wound shield |
BRPI0807972A2 (pt) | 2007-01-24 | 2014-06-10 | Glaxo Group Ltd | Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1 |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
US10100030B2 (en) | 2013-11-08 | 2018-10-16 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
US10538491B2 (en) | 2015-03-16 | 2020-01-21 | Vanderbilt University | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators |
CN115531553A (zh) * | 2015-12-22 | 2022-12-30 | 武田药品工业株式会社 | 内体g蛋白-偶联的受体的三部分调节剂 |
CN111918647A (zh) | 2018-02-26 | 2020-11-10 | 圣拉斐尔医院有限公司 | 用于治疗眼痛的nk-1拮抗剂 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
US5612337A (en) | 1993-12-29 | 1997-03-18 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
EP1061926A2 (en) | 1998-03-19 | 2000-12-27 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use as tachykinin receptor antagonists |
JPH11322748A (ja) * | 1998-03-19 | 1999-11-24 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および用途 |
NZ513370A (en) * | 1999-02-24 | 2004-02-27 | F | 3-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
SE1035115T5 (sv) | 1999-02-24 | 2015-08-04 | Hoffmann La Roche | 4-fenylpyridin-derivat och deras anvaendning som NK-1 receptor-antagonister |
WO2000050398A2 (en) * | 1999-02-24 | 2000-08-31 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
US6291465B1 (en) * | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
DK1103545T3 (da) * | 1999-11-29 | 2004-03-15 | Hoffmann La Roche | 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
RU2266284C2 (ru) * | 2000-07-14 | 2005-12-20 | Ф.Хоффманн-Ля Рош Аг | N-окиси производных 4-фенилпиридина, лекарственное средство, содержащее их |
-
2001
- 2001-07-06 TW TW090116615A patent/TWI287003B/zh not_active IP Right Cessation
- 2001-07-09 US US09/901,311 patent/US6576762B2/en not_active Expired - Lifetime
- 2001-07-17 JO JO2001117A patent/JO2321B1/en active
- 2001-07-18 PE PE2001000730A patent/PE20020258A1/es not_active Application Discontinuation
- 2001-07-19 PA PA20018522801A patent/PA8522801A1/es unknown
- 2001-07-20 PT PT01960529T patent/PT1305319E/pt unknown
- 2001-07-20 AU AU8200501A patent/AU8200501A/xx active Pending
- 2001-07-20 WO PCT/EP2001/008432 patent/WO2002008232A1/en active IP Right Grant
- 2001-07-20 AU AU2001282005A patent/AU2001282005B2/en not_active Expired
- 2001-07-20 HU HU0301272A patent/HU229231B1/hu unknown
- 2001-07-20 CN CNB018132863A patent/CN1192032C/zh not_active Expired - Lifetime
- 2001-07-20 KR KR10-2003-7001022A patent/KR100527214B1/ko active IP Right Grant
- 2001-07-20 JP JP2002514138A patent/JP4118673B2/ja not_active Expired - Lifetime
- 2001-07-20 ES ES01960529T patent/ES2260265T3/es not_active Expired - Lifetime
- 2001-07-20 RU RU2003104794/04A patent/RU2276139C2/ru not_active IP Right Cessation
- 2001-07-20 DK DK01960529T patent/DK1305319T3/da active
- 2001-07-20 MY MYPI20013445A patent/MY129224A/en unknown
- 2001-07-20 BR BR0112695-4A patent/BR0112695A/pt not_active IP Right Cessation
- 2001-07-20 CZ CZ2003528A patent/CZ2003528A3/cs unknown
- 2001-07-20 MX MXPA03000367A patent/MXPA03000367A/es active IP Right Grant
- 2001-07-20 NZ NZ523452A patent/NZ523452A/en unknown
- 2001-07-20 AT AT01960529T patent/ATE322496T1/de active
- 2001-07-20 EP EP01960529A patent/EP1305319B1/en not_active Expired - Lifetime
- 2001-07-20 CA CA2416874A patent/CA2416874C/en not_active Expired - Lifetime
- 2001-07-20 YU YU2803A patent/YU2803A/sh unknown
- 2001-07-20 PL PL01366173A patent/PL366173A1/xx not_active Application Discontinuation
- 2001-07-20 IL IL15383701A patent/IL153837A0/xx active IP Right Grant
- 2001-07-20 SI SI200130532T patent/SI1305319T1/sl unknown
- 2001-07-20 DE DE60118569T patent/DE60118569T2/de not_active Expired - Lifetime
- 2001-07-23 GT GT200100148A patent/GT200100148A/es unknown
- 2001-07-23 UY UY26851A patent/UY26851A1/es not_active Application Discontinuation
- 2001-07-23 AR ARP010103499A patent/AR029875A1/es not_active Application Discontinuation
-
2002
- 2002-10-29 US US10/282,357 patent/US6624176B2/en not_active Expired - Lifetime
-
2003
- 2003-01-07 IL IL153837A patent/IL153837A/en unknown
- 2003-01-08 ZA ZA200300219A patent/ZA200300219B/en unknown
- 2003-01-17 HR HR20030031A patent/HRP20030031A2/xx not_active Application Discontinuation
- 2003-01-22 MA MA27006A patent/MA26933A1/fr unknown
- 2003-01-23 EC EC2003004446A patent/ECSP034446A/es unknown
- 2003-01-23 NO NO20030353A patent/NO20030353L/no not_active Application Discontinuation
-
2004
- 2004-02-16 HK HK04101077A patent/HK1058360A1/xx not_active IP Right Cessation
-
2006
- 2006-07-04 CY CY20061100918T patent/CY1106113T1/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101119365B1 (ko) | 2006-05-31 | 2012-03-07 | 에프. 호프만-라 로슈 아게 | 아릴-4-에틴일-아이속사졸 유도체 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100527214B1 (ko) | 뉴로키닌-1 수용체 길항제로서의 4-페닐-피리딘 유도체 | |
KR100518201B1 (ko) | 뉴로키닌-1 수용체 길항물질로서의 4-페닐-피리딘 유도체 | |
KR100384904B1 (ko) | 4-페닐-피리딘 유도체 | |
US6225316B1 (en) | 3-phenyl-pyridine-derivatives | |
AU2001282005A1 (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
AU2002212118A1 (en) | 4-phenyl-pyridine derivatives as Neurokinin-1 receptor antagonists | |
JP2004504301A (ja) | Nk1受容体拮抗物質プロドラッグとしての4−フェニル−ピリジン誘導体のn−オキシド | |
EP1103545B1 (en) | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide | |
EP1856052B1 (en) | Nk1 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121030 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131030 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141030 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161028 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170929 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180928 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20190924 Year of fee payment: 15 |